

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		6045
09/719,889	02/21/2001	Earl R. Owen	12724-002001	00.15
7590 09/30/2002 Fish & Richardson Suite 500 4350 La Jolla Village Drive San Diego, CA 92122		EXAMINER CHISM, BILLY D		
		34 2.155 2, 2		

Please find below and/or attached an Office communication concerning this application or proceeding.

, i	Application No.	Applicant(s)
	09/719,889	OWEN ET AL.
Office Action Summary	Examiner	Art Unit
		1653
The MAILING DATE of this communication ap	opears on the cover sheet	with the correspondence address
The MAILING DATE of this communication a		MONTHIO EDOM
eriod for Reply	PLY IS SET TO EXPIRE 3	3 MONTH(S) FROM
 Extensions of time may be available under the provisions of 37 CFR of after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a refunction of the period for reply is specified above, the maximum statutory perion of the period for reply within the set or extended period for reply will, by state. Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b). 	en.136(a). In no event, nowever, may reply within the statutory minimum of the food will apply and will expire SIX (6) Matute, cause the application to become ailing date of this communication, even	of thirty (30) days will be considered timely. MONTHS from the mailing date of this communication.
Status 1) ☐ Responsive to communication(s) filed on	·	
		ما مشمس خطاعه و در
2a) This action is 1 it 2.	المسما	matters, prosecution as to the merits is 5 C.D. 11, 453 O.G. 213.
closed in accordance with the product	der Ex parte Quayle, 193t	O Orbot (1) (1-4 orbot)
Disposition of Claims		
- and a sector pending in the applica	drawn from consideration	1.
4a) Of the above claim(s) is/are with	nurawii itoin consideratioi	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-28</u> is/are rejected.		
is/are objected to.	adlar alastian requirement	ıt.
8) Claim(s) are subject to restriction a	and/or election requiremen	
Application Papers		
9) The specification is objected to by the Example 1		o by the Examiner.
10) The drawing(s) filed on is/are: a) is/are: a)	accepted of b/L objects	abeyance. See 37 CFR 1.85(a).
10) The drawing(s) filed on is/are: a) Applicant may not request that any objection 11) The proposed drawing correction filed on	is: a) ☐ annroved h	b) disapproved by the Examiner.
The second drawing correction filed on	IS. a) approved a	-/-
If approved, corrected drawings are required	a in reply to this chief and	
12) ☐ The oath or declaration is objected to by the	THE EXCENTION.	
440 420		I.S.C. § 119(a)-(d) or (f).
13) Acknowledgment is made of a claim for t	toreign priority under 35 C	v
None of:		
doct	suments have been receiv	ed in Application No.
	anto have been receive	Ved III Application
3. Copies of the certified copies of the application from the Internation	the priority documents have onal Bureau (PCT Rule 17.	7.2(a)). pies not received.
application from the Internatio * See the attached detailed Office action fo	omestic estate under Cot	U.S.C. § 119(e) (to a provisional application
14) ☐ Acknowledgment is made of a claim for d	domestic priority under 55	on has been received.
a) ☐ The translation of the foreign languation of the foreign languat	uage provisional applicatio domestic priority under 35	5 U.S.C. §§ 120 and/or 121.
Attachment(s)		Summary (PTO-413) Paper No(s)
1) Notice of References Cited (PTO-892)	D-948) 5) 🔲 1	Notice of Informal Patent Application (P10-132)
2) Notice of Draftsperson's Patent Brawing (1970-1449) Pape 3) Information Disclosure Statement(s) (PTO-1449) Pape		Part of Paper No. 7

Art Unit: 1653

DETAILED ACTION

Specification

1. The abstract of the disclosure is objected to because of the use of terminology/phraseology like "e.g.". Such reference to specific examples should be removed. Correction is required. See MPEP § 608.01(b).

Claim Rejections - 35 USC § 112

- The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 3. Claims 1-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is indefinite as it is not clear in the wording of the claim whether the recitation of "which are denatured" is a prophetic statement regarding when the denaturing will take place. It should be more concise in the claim whether the solder alone comprises a denatured protein or if the solder will comprise a denatured protein after administration and repair has began.

Claims 1, 11, 17 and 19 are indefinite for the recitation of the term "substantially solid solder," wherein substantially solid is not clear regarding the malleability, consistency or durability.

Claims 6-7 are indefinite for lacking antecedent basis in claim 1 for the recitation of an adjuvant in claim 1.

Art Unit: 1653

Claims 8-9 are indefinite for lacking antecedent basis in claim 1 for the recitation of "a material."

Claims 19-21 are indefinite for lacking antecedent basis in claim 11 for the recitation of a "dye."

Claims 23-25 are indefinite for lacking antecedent basis in claim 11 for the recitation of "shaping."

Claim 26 is indefinite for lacking antecedent basis in claim 11 for the recitation of "sterilizing."

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claims 1-4, 6-7, 11-14, 16-17 and 27 are rejected under 35 U.S.C. 102(a) as being anticipated by Poppas, U.S. Patent No. 5,713,891. Poppas teaches the use of a denatured protein/dye solder with an adjuvant (i.e. albumin, indocyanine green and growth factors) for the repair of damaged biological tissues. Claims 1-2 require a denatured protein solder, see column 11, lines 6-9. Claim 3 requires the solder to be albumin, elastin, collagen or fibrinogen, see column 5, lines 3-7. Claims 4-5 require a dye, see column 5, lines 20-37. Claims 6-7 require an

Application/Control Number: 09/719,889

Art Unit: 1653

adjuvant for promoting rapid or more complete tissue healing, see column 5, lines 53-67 and column 6, lines 1-54. Claims 11-13 set forth method steps for making by forming solder, denaturing solder, and drying solder, see column 5, lines 1-67 and col6 lines 1-67. Claims 16 requires exposing composition to a compound for denaturing, see column 11, lines 14-26. Claim 17 requires mixing of biomolecules with solvent to form composition, see column 5 lines 53-67 and column 6 lines 1-54. Claim 27 requires the methods of repairing tissue comprising applying solder and exposing to energy for time to allow for repair, see column 11, lines 6-35.

Claims 1-3, 8-9, 11-17, 22, 24-25 and 27-28 are rejected under 35 U.S.C. 102(a) as being anticipated by Sawyer *et al.* U.S. Patent No. 5,749,895. Sawyer *et al.* teach the use of a denatured protein patch solder, to be used with an additional material mesh for support and with a material for solder strength and further comprising the steps of denaturing, solidifying and administering the solder. Claims 1-2 require a denatured protein solder, see column 12, lines 22-36. Claims 8-9 require a material for strengthening the solder, see column 3 lines 26-30. Claims 11-17 require forming the solder (column 6, line 14 through column 9, line 48), denaturing the solder by thermal energy (column 8, lines 16-19) or by mixing a composition (column 8, lines 23-25), drying the solder (column 8 lines 31-32).

6. Claims 1-2 and 27-28 are rejected under 35 U.S.C. 102(b) as being anticipated by Sawyer, U.S. Patent No. 5,156,613. Sawyer teaches the use of a protein solder by denaturing a collagen filler material with energy for the purpose of soldering biological tissues by forming the composition, denaturing the composition and drying the composition and by moistening the composition prior to welding. (column 4, lines 50-60, column 9, lines 46-50 and column 10, lines 24-28) (column 7 lines 32-33). Claims 1-2 require protein solder, see column 9, lines 27-30.

Art Unit: 1653

Claims 27-28 require moistening solder prior applying, then applying the protein solder and exposing to energy for bonding, see column 9 lines 46-50 and lines 24-31.

Conclusion

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 703-306-5815. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 703-308-2329. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

B. Dell Chism

16 September 2002

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600